Market Overview

UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat

Related MDT
Covidien Earnings Preview: Has Merger News Shaken Expectations?
5 New Medical Technologies For Diabetics
FT: 25 More Firms May Seek Tax Breaks Overseas (Fox Business)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.

Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42.75 on Wednesday.

Posted-In: Deutsche BankAnalyst Color Price Target Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free